Highlight
– The Cutaneous Lymphoma International Consortium analyzed survival in 1,275 patients with advanced mycosis fungoides (MF) and Sézary syndrome (SS).
– Four independent prognostic markers—stage IV disease, age over 60, large-cell transformation, and elevated lactate dehydrogenase (LDH)—were linked to worse survival.
– A prognostic index categorizing patients into low, intermediate, and high risk groups demonstrated distinct 5-year survival rates of 68%, 44%, and 28%, respectively.
– This large multicenter dataset provides a new tool to refine prognosis and guide treatment strategies in advanced MF/SS.
